Evidence map›Paper›PMID 41507547›Full record

ArticleDiscover oncology2026

Identification of GPD1L as a potential prognosis biomarker and associated with colorectal cancer progression.

Ya-Rui Liu, Ying Zeng, Chao Mei, Yun-Hua Xu, Hai-Bo Zhang, Rui Liang, Guo Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ya-Rui LiuDepartment of Pharmacy, Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Ying ZengDepartment of Pharmacy, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, China.
Chao MeiDepartment of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Yun-Hua XuDepartment of Pharmacology, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Hai-Bo ZhangDepartment of Pharmacy, Hangzhou Women's Hospital (Hangzhou Maternity and Child Health Care Hospital), Hangzhou, China.
Rui LiangSchool of Basic Medical Science, Suzhou Vocational Health College, Suzhou, China.
Guo WangDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, China. 207082@csu.edu.cn.

Funding

Hubei Provincial Health Commission Guiding Project No. J2023F009Maternal and Child Health Hospital of Hubei Province Research Project No. 2021SFYY003National Natural Science Foundation of China No. 81673516National Natural Science Foundation of China No. 82003870Scientific and Technological Innovation Team Building Program of Suzhou Vocational Health College No. SZWZYTD202205
6 · The paper itself

Abstract

backgroundColorectal cancer (CRC) ranks high in both global incidence and mortality rates. The discovery of potential biomarkers and therapeutic targets can effectively improve early diagnosis, treatment efficacy, and prognosis for CRC patients.

methodsGenes that were abnormally expressed in CRC tumors and associated with patients’ prognosis were first screened in The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases; Clinical CRC samples were used to validate the results. The correlation between clinical characteristics and candidate genes, as well as their role in CRC cell proliferation, migration, invasion capability, and the cell cycle were analyzed.

resultsThe study indicated that glycerol-3-phosphate dehydrogenase 1-like (GPD1L) was significantly down-regulated in CRC tumor tissues and served as an independent prognostic factor for OS and RFS of CRC patients. It was also associated with TNM staging, lymph node metastasis, tumor size, and tumor location. Inhibiting GPD1L expression significantly up-regulated the proliferation, migration, and invasion capabilities of CRC cells.

conclusionsGPD1L may serve as a prognostic biomarker for patients with CRC and participate in the regulation of CRC cell proliferation, migration, and invasion capability.

Indexed as

BiomarkersColorectal cancerGPD1LPrognosisTherapeutic targets

Identifiers

PMID41507547
PMCPMC12783402

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.